DALLAS / May 31, 2023 / Business Wire / Tenet Healthcare Corporation (NYSE: THC) is scheduled to present at the 44th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 13, 2023, beginning at 9:20 a.m. Pacific time (12:20 p.m. Eastern Time).
A live webcast and audio archive of the event may be accessed through the investor relations section of Tenet’s website at https://investor.tenethealth.com/. The replay will be available for 30 days.
About Tenet Healthcare
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates or has ownership interests in more than 465 ambulatory surgery centers and surgical hospitals. We also operate 61 acute care and specialty hospitals, approximately 110 other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers, and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.
Last Trade: | US$121.81 |
Daily Change: | 1.37 1.14 |
Daily Volume: | 934,847 |
Market Cap: | US$11.580B |
February 12, 2025 October 29, 2024 July 24, 2024 April 30, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load